Spero Therapeutics (SPRO) to Release Quarterly Earnings on Wednesday

Posted by Lauren Steadman on May 20th, 2025

Spero Therapeutics (NASDAQ:SPRO – Get Free Report) will likely be issuing its Q1 2025 quarterly earnings data before the market opens on Wednesday, May 21st. Analysts expect the company to announce earnings of ($0.44) per share for the quarter.

Spero Therapeutics (NASDAQ:SPRO – Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.30. Spero Therapeutics had a net margin of 3.30% and a return on equity of 4.03%. The business had revenue of $5.87 million for the quarter, compared to analysts’ expectations of $11.00 million. On average, analysts expect Spero Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Spero Therapeutics Price Performance

NASDAQ SPRO opened at $0.69 on Tuesday. Spero Therapeutics has a 1 year low of $0.51 and a 1 year high of $1.60. The stock has a market capitalization of $38.54 million, a PE ratio of 9.85 and a beta of 0.23. The company’s 50 day simple moving average is $0.69 and its two-hundred day simple moving average is $0.88.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and issued a $5.00 target price on shares of Spero Therapeutics in a research note on Thursday, January 30th.

Read Our Latest Report on Spero Therapeutics

Spero Therapeutics Company Profile

(Get Free Report)

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.